Tirzepatide
Jump to navigation
Jump to search
A Tirzepatide is a synthetic polypeptide consisting of 39 amino acids.
- Context:
- Counter-Example(s):
- See: Molecular Metabolism, Glucagon-Like Peptide-1.
References
2023
- (Wikipedia, 2023) ⇒ https://en.wikipedia.org/wiki/tirzepatide Retrieved:2023-4-12.
- Tirzepatide, sold under the brand name Mounjaro, is an antidiabetic medication used for the treatment of type 2 diabetes.[1] [2] Tirzepatide is administered once weekly through subcutaneous injection (under the skin).[1][3] The most common side effects include nausea, vomiting, diarrhea, decreased appetite, constipation, upper abdominal discomfort, and abdominal pain.[1][3] Glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) are hormones involved in blood sugar control.[3] After a person has eaten, these hormones are secreted by cells of the intestines and in turn cause the secretion of insulin. Tirzepatide is a GIP-analogue that activates both the GLP-1 and GIP receptors, leading to improved blood sugar control.[3] Tirzepatide was approved for medical use in the United States in May 2022,[1][3] in the European Union in September 2022,[4] in Canada in November 2022, and in Australia in December 2022.[5] The US Food and Drug Administration (FDA) considers it to be a first-in-class medication.
- ↑ 1.0 1.1 1.2 1.3 Cite error: Invalid
<ref>tag; no text was provided for refs namedMounjaro FDA label - ↑ Cite error: Invalid
<ref>tag; no text was provided for refs namedmoa - ↑ 3.0 3.1 3.2 3.3 3.4 Cite error: Invalid
<ref>tag; no text was provided for refs namedFDA PR 20220513 - ↑ Cite error: Invalid
<ref>tag; no text was provided for refs namedMounjaro EPAR - ↑ Cite error: Invalid
<ref>tag; no text was provided for refs namedTGA Mounjaro